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Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in 
the world and it is thought that 1 in 10 of the adult global population have the disease 
(1). Despite this, COPD has not received the level of attention it requires by 
Ministries of Health and health services, particularly in low- and middle-income 
countries (LMIC), where most of the people with this disease live and where there is 
limited access to spirometry to confirm the diagnosis, little effective therapy and 
minimal public health policy on prevention. In 2012 the World Health Assembly 
endorsed the “25 by 25 goal”, focusing on reducing premature deaths from non-
communicable disease (NCDs) by 25% by the year 2025 (2), but whilst the third 
United Nations (UN) High Level Meeting (HLM) on NCDs in September 2018 
acknowledged that “action to realize the commitments made for the prevention and 
control of non-communicable diseases is inadequate” many felt the Political 
Declaration lacked ambition and was a missed opportunity to address the global 
NCD epidemic. As COPD is a highly prevalent NCD, is the third most common 
causes of premature death and is highly preventable we, the Board of Directors 
(BoD) of the Global Initiative for Chronic Obstructive Lung Disease (GOLD), are 
especially concerned that the disease has not been taken seriously enough by the 
UN/World Health Organization (WHO): not enough is being done to address the 
increasing prevalence, morbidity and mortality caused by COPD and there is no 
coordinated strategy to encourage countries to prioritise and resource its prevention 
and management. 
It is important that governments are made aware that COPD can no longer be seen 
as a condition solely caused by smoking in adult life, although this is certainly a 
major risk factor. From a global perspective, exposure to biomass fumes and air 
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pollution in adult life are important risk factors and there is now good evidence that 
poor pre and postnatal lung growth as a result of malnutrition, infections and/or 
passive exposure to pollutants also leads to COPD (3-5). The contribution of these 
different risks factors varies. In high socio-demographic index (SDI) countries, the 
behavioural risks (smoking and second-hand smoke) are the most important causes, 
while environmental exposures and early life events appear to explain the majority of 
burden in lower-SDI quintiles. Within many countries the inequalities in burden and 
mortality due to COPD relate to poverty (5) and at a global level COPD is more 
prevalent in countries where inequalities in living standards are more extreme. 
COPD is one of the most important and preventable cause of global inequalities in 
health outcomes. This new understanding of COPD opens novel windows of 
opportunity for prevention, early diagnosis and more effective therapeutic 
interventions.
The Global Burden of Disease (GBD) study estimated that between 1990 and 2015 
the prevalence of COPD increased by 44·2% and that in 2015 COPD affected 104·7 
million men and 69·7 million women globally (6). These estimates are based on data 
from surveys using standardised questionnaires and spirometry such as those that 
have been done under the umbrella of the Burden of Obstructive Lung Disease 
(BOLD) study (7) and similar studies in Latin America (8) and Europe (9). However, 
using some of the same data, the Global Health Epidemiology Reference Group 
concluded that the prevalence was much higher and estimated that approximately 
384 million people globally had COPD in 2010 (10). Since reliable data on 
prevalence are not available for many LMIC there is an urgent need for 
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standardisation in data collection to allow the true burden to be calculated and to 
monitor changes (6).
COPD caused approximately 3.2 million deaths worldwide in 2017 (11) and there 
was a 17.5% increase in the number of deaths between 2007 and 2017. This is a 
much faster increase than predicted by the first GBD analysis (12). Over this period 
age-standardised mortality rates appear to have fallen in some countries, including 
LMICs but this may unfortunately only be temporary and probably mirrors the 
decreases observed in developed countries in the last century, when life expectancy 
improved because of better nutrition and treatment of infectious diseases. Over 
time, the positive trends are likely to be reversed as the negative consequences of 
tobacco use and other risk factors become more prevalent.
TIME TO TAKE COPD SERIOUSLY
COPD is currently diagnosed in mid-life or later. Individuals must therefore survive 
long enough to develop symptoms, and by this time they are already at risk of 
premature death. Until recently the mean life expectancy of the populations in many 
LMIC was so low that survival to an age when COPD manifests was unlikely. 
However, improvements in life expectancy in Latin America, Africa and South East 
Asia over the last 50 years, together with reductions in childhood mortality mean 
that COPD is rapidly becoming an even more significant health issue in these 
regions. In addition, the epidemic of tobacco smoking is at its height in middle 
income countries and is developing in low income countries, particularly in sub-
Saharan African countries that are seen by tobacco companies as one of the last of 
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the ‘emerging markets’ left to be targeted aggressively (13). Without action, the 
global burden of COPD will grow enormously in the few next decades.
As part of a strategy to explore potential ways to improve the prevention, diagnosis 
and management of COPD we held a one-day Summit in September 2018 to 
consider information on the prevalence, causes, clinical presentation, mortality, 
resources and approaches for COPD provided by local experts in LMIC societies 
with high COPD burden (Halpin et al, forthcoming). 
The information presented confirmed that the development of COPD in these 
settings is multifactorial. The Summit discussed the fact that there have been very 
few pathophysiological studies to understand differences between COPD caused by 
poor lung development versus adult exposures, and between COPD due to smoking 
tobacco and exposure to biomass smoke and pollution. This is particularly true in 
terms of symptom patterns, disease progression, long term outcomes, and response 
to treatments. Studies must be done to investigate these issues. The summit also 
concluded that there are major deficiencies in epidemiological data in many regions, 
particularly outside cities, and that there is little public awareness of COPD as a 
major health problem in LMIC. There is a need to raise awareness of COPD among 
health workers, to emphasise the importance of accurate diagnosis, to make 
spirometry easily available and to train health workers in its use. For example, the 
Summit heard that in Malawi, a country of 19.3 million people, there has been only 
one spirometer for clinical diagnostic purposes for many years. The BoD agreed that 
there is also a need to identify lung function abnormalities at an earlier age. 
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The Summit heard of the problems with access to effective pharmacological and 
non-pharmacological therapy in LMIC. There are wide disparities between countries 
in access to healthcare (14) but access to basic COPD medication shows much 
greater inequalities and spirometry for diagnosis is not widely available (15). The 
only long-acting bronchodilator in the WHO list of essential medications is formoterol, 
but it is only listed in combination with budesonide (16) and currently, no long-acting 
muscarinic antagonist bronchodilators are listed. Short acting beta agonist (SABA) 
do feature in the list as do inhaled corticosteroids (ICS) but ICS alone are not 
indicated in COPD. The Summit heard of the low availability and affordability of 
these inhaled therapies in most LMIC and contrasted this to the widespread 
availability of cigarettes. Much more must be done to ensure reliable supplies of 
medication at an affordable price in LMIC. Non-pharmacological interventions such 
as pulmonary rehabilitation and palliative care must also be made available.
Although the focus of the Summit was the burden of COPD in LMIC, we are also 
aware that the burden of COPD in upper-middle and high income countries, 
including China, remains high (17). There is substantial under-diagnosis in Europe 
and North America, evidence of inappropriate pharmacotherapy and limited access 
to non-pharmacological therapies. In high income countries COPD remains one of 
the major causes or morbidity and mortality and governments and health services in 
these countries also need to give COPD the priority that it deserves. 
The Summit concluded that time is overdue for civil society, individual health 
services, Ministries of Health and NGOs and international agencies, including the 
WHO and UN, to take COPD seriously by recognizing the universal burden of COPD 
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and enacting policies and practices to address the impact of the disease, particularly 
in LMIC. Unless this happens, there will be needless suffering, increasing 
inequalities and substantial preventable direct and indirect costs from COPD. We are 
aware that collaborations such as the Global Alliance Against Respiratory Diseases 
(GARD) (https://www.who.int/gard/en/) launched by WHO in 2006 and the Forum of 
International Respiratory Societies (FIRS) (https://www.firsnet.org/) have been 
working for over a decade to raise awareness of chronic respiratory disease at a 
global level and GOLD is a partner in these alliances, but we are concerned that the 
breadth of these initiatives means that progress on improving outcomes for people 
with COPD is too slow. A number of excellent projects such as FRESH AIR aim to 
improve the prevention, diagnosis and treatment of chronic lung diseases in contexts 
with limited healthcare resources (18), but more needs to be done. Initiatives such as 
the Practical Approach to Care Kit (PACK) may hold the key to ensuring that 
effective COPD care can be delivered in LMICs through integrated primary care-
focused guides, training strategies, health systems strengthening interventions and 
monitoring and evaluation kits (19) but governments in LMIC need to embrace such 
initiatives.
The GOLD BoD challenges all relevant parties to form a coalition with GOLD to 
achieve our ambition of reducing the impact of COPD worldwide. We must work 
together to prevent the development of COPD by reducing exposure to risk factors, 
to ensure the diagnosis is made as early as possible and to ensure all patients 
around the world receive effective therapy. We want to see a reduction in the 
number of people suffering and dying from COPD in all countries. The WHO and UN 
must do all they can to ensure Ministries of Health, supported by national and 
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international professional societies and the pharmaceutical industry, to commit to 
actions required to achieve these goals (Table 1) and monitor progress. We call for a 
whole system approach that moves COPD management up a ladder of quality, 
driven by action and political pressure led by these organisations and underpinned 
by the WHO (Figure 1). Contributors to the 2019 UN HLM on UHC must ensure that 
a minimum essential package of provisions for raising awareness of the disease, 
prevention, diagnosis and management is included in the Political Declaration and 
that they are backed up by sufficient financial resources and progress on 
implementation is monitored.
1790 words
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Table 1. Actions required to improve global management of COPD
 Increase awareness of COPD at all levels of society
 Prevent COPD
- Improve maternal nutrition and promote healthy lifestyles (e.g., 
avoiding smoking during pregnancy)
- Minimise childhood exposure to indoor and outdoor air pollution
- Reduce adult smoking and encourage all countries to ratify the WHO 
Framework Convention on Tobacco Control.
 Diagnose COPD earlier
- Promote use of simple questionnaires to identify subjects likely to 
have COPD
- Improve the availability and access to spirometry
- Use new technology to offer alternatives to conventional spirometry
- Train community health workers in early COPD detection
- Assess lung function at an early age 
 Treat COPD effectively and earlier
- Implement and promote smoking cessation programmes. 
- Decrease exposure to pollutants.
- Ensure drugs with proven efficacy and safety are available
- Promote awareness of evidence-based management guidelines
- Train community health workers in basic COPD management
- Make medicines available through access programmes
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increase clinician & public awareness
make spirometry available to all who need it
collect accurate epidemiological data
ensure WHO essential medications available & affordable
reduce indoor & outdoor pollution to safe levels
reduce intra-uterine & childhood risk factors to safe levels
develop tobacco prevention & quitting programmes
Government &
Professional
Groups Action
train community health workers
promote awareness of evidence based guidelines
make all therapy available & affordable
Figure 1. Whole system approach to taking COPD seriously. 
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ensure WHO essential medications available & affordable 
reduce indoor & outdoor pollution to safe levels
reduce intra-uterine & childhood risk factors to safe levels
develop tobacco prevention & quitting programmes 
Government & 
Professional 
Groups Action
train community health workers
promote awareness of evidence based guidelines
make all therapy available & affordable 
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